Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Double-blind, Randomized, Placebo-controlled, Single- and Multiple-dose Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PB-718 Following Subcutaneous Administration in Healthy Subjects

NCT05021666 is registered in ClinicalTrials.gov with PegBio Co., Ltd. as lead sponsor.

NCT NCT05021666
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05021666 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Double-blind, Randomized, Placebo-controlled, Single- and Multiple-dose Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PB-718 Following Subcutaneous Administration in Healthy Subjects
Lead sponsor
PegBio Co., Ltd.
Phase
Phase 1
Overall status
Completed
Start date
July 29, 2020
Completion date
August 12, 2022
Enrollment
82 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

healthy subjects